Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clonazepam
Drug ID BADD_D00501
Description A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop [FDA Label] [L5572, F3763, F3787, F3796]. The agent has also been indicated for treating panic disorder [FDA Label] [A175438, L5572, F3763, F3787, F3796]. The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses [FDA Label] [A175438, A175441, L5572, F3763, F3787, F3796]. Since being first patented in 1960 and then released for sale from Roche in the US in 1975 [T469, T472], clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately, however, like most benzodiazepines, clonazepam use has also been associated with recreational use and drug abuse [FDA Label] [L5572, F3763, F3787, F3796].
Indications and Usage Clonazepam is used as an anticonvulsant in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. It can also be used for the treatment of panic disorders.
Marketing Status Prescription; Discontinued
ATC Code N03AE01
DrugBank ID DB01068
KEGG ID D00280
MeSH ID D002998
PubChem ID 2802
TTD Drug ID D0CP4E
NDC Product Code 57664-784; 43063-794; 17856-0834; 0228-3004; 62756-110; 0093-9290; 60429-525; 71335-1843; 63629-8988; 70518-1297; 70518-2334; 51552-1567; 68071-5163; 62332-368; 60687-555; 80425-0125; 0615-8235; 68788-7181; 50090-4299; 60760-273; 68788-7394; 49884-308; 0004-0058; 49884-310; 63629-1207; 68071-4135; 55154-6831; 62332-364; 70518-1521; 71610-084; 43353-308; 71610-366; 43547-408; 57664-785; 61919-485; 51407-524; 80425-0135; 63629-1203; 50090-4842; 0615-8234; 12828-0060; 58118-0832; 46708-367; 61919-058; 55700-564; 46708-368; 57664-787; 48087-0038; 53002-7451; 51927-4663; 50090-2022; 71335-0022; 70518-2485; 71610-061; 67544-529; 45865-575; 71610-367; 62332-367; 63187-603; 62332-365; 49884-309; 70518-3144; 0004-0068; 68071-2310; 46708-366; 60687-544; 67544-288; 0093-9291; 72189-081; 71610-040; 50090-3467; 70518-1353; 49884-306; 50090-2088; 16729-137; 71335-0113; 68788-7738; 0093-3213; 70518-1801; 63629-8226; 71205-529; 43353-307; 43063-797; 71610-390; 61269-605; 60429-526; 63629-1202; 63187-888; 43547-406; 62332-366; 48087-0014; 63629-1205; 71610-085; 16729-138; 0395-8179; 68071-4021; 68071-5247; 55154-8125; 70518-2467; 0004-0098; 71610-363; 60429-524; 55700-830; 0228-3003; 63187-226; 0093-9294; 70518-2232; 49884-307; 0093-3212; 71610-039; 70518-1559; 61269-610; 43063-788; 71205-252; 71610-075; 67544-412; 71554-021; 0615-8236; 63629-1206; 70518-2507; 61269-620; 16729-136; 0093-9293; 71335-0333; 63629-1201; 63629-7649; 70518-2392; 63629-1116; 71335-1810; 71610-023; 71335-1856; 71610-368; 57664-783; 43547-407; 70518-2533; 64330-019; 57664-786; 50090-5399; 63629-1204; 0093-9292; 0093-0832; 46708-364; 67544-256; 46708-365; 17856-0835
Synonyms Clonazepam | 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- | Rivotril | Klonopin | Antelepsin | Ro 5-4023 | Ro 54023
Chemical Information
Molecular Formula C15H10ClN3O3
CAS Registry Number 1622-61-3
SMILES C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory tract infection22.07.07.001; 11.01.08.0170.000129%Not Available
Unevaluable event08.01.03.051--Not Available
Poor quality sleep17.15.04.002; 19.02.05.0050.000129%Not Available
Cystitis noninfective20.03.02.001--
Body temperature fluctuation13.15.01.0310.000129%Not Available
Bowel movement irregularity07.02.03.0030.000129%Not Available
Pyramidal tract syndrome17.05.05.0030.000129%
Gastrointestinal inflammation07.08.03.007--Not Available
Skin abrasion23.03.11.018; 12.01.06.010--Not Available
Substance abuse19.07.02.0060.000259%Not Available
Treatment failure08.06.01.0170.000051%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000051%Not Available
Acute kidney injury20.01.03.016--
Bladder dysfunction20.03.03.002--Not Available
Foetal growth restriction18.03.01.0020.000259%
Gestational hypertension24.08.07.004; 18.02.03.0040.000259%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.000259%
Glassy eyes06.08.03.021; 08.01.03.055--Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021--Not Available
Candida infection11.03.03.021--
Multiple organ dysfunction syndrome08.01.03.0570.000084%
Frustration tolerance decreased19.04.02.0160.000129%Not Available
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Alcohol interaction08.06.03.0030.000129%Not Available
Anion gap abnormal13.02.01.0190.000051%Not Available
Apnoeic attack22.02.01.027; 17.02.05.0510.000129%Not Available
Coeliac disease07.17.01.008; 14.02.01.007; 10.04.04.0120.000646%Not Available
Dengue fever23.09.03.011; 11.05.23.0010.000129%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.000194%Not Available
Respiratory depth decreased22.02.01.0110.000034%Not Available
The 17th Page    First    Pre   17 18    Next   Last    Total 18 Pages